Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

188.41 +2.73 (+1.47%)

Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AstraZeneca PLC - American Depositary Shares

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

June 24, 2026

From AstraZeneca

Via Business Wire

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

June 22, 2026

Via Investor Brand Network

Topics Artificial Intelligence

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

June 22, 2026

Via Investor Brand Network

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

June 12, 2026

From AstraZeneca

Via Business Wire

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

June 02, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

June 01, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

May 28, 2026

From AstraZeneca

Via Business Wire

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

May 22, 2026

From AstraZeneca

Via Business Wire

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026

From AstraZeneca

Via Business Wire

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

May 15, 2026

From AstraZeneca

Via Business Wire

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

May 14, 2026

From AstraZeneca

Via Business Wire

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

April 30, 2026

From AstraZeneca

Via Business Wire

AstraZeneca results: Q1 2026

April 29, 2026

From AstraZeneca

Via Business Wire

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

April 28, 2026

From AstraZeneca

Via Business Wire

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

April 27, 2026

From AstraZeneca

Via Business Wire

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

April 20, 2026

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

April 02, 2026

From AstraZeneca

Via Business Wire

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

March 27, 2026

From AstraZeneca

Via Business Wire

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

March 10, 2026

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

March 09, 2026

From AstraZeneca

Via Business Wire

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

February 20, 2026

From AstraZeneca

Via Business Wire

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

February 13, 2026

From AstraZeneca

Via Business Wire

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

February 11, 2026

From AstraZeneca

Via Business Wire

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

AstraZeneca results: FY and Q4 2025

February 10, 2026

From AstraZeneca

Via Business Wire

DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

February 03, 2026

From AstraZeneca

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.